Patrick Schöffski, MD, of the University Hospital Leuven, discusses a phase III study in which he and his colleagues found, for the first time in soft-tissue sarcomas, a significant overall survival benefit of a single agent compared to a standard treatment (Abstract LBA10502).
John Smyth, MD, of the University of Edinburgh, discusses oncology from an international point of view.
John L. Marshall, MD, of Georgetown University, discusses how the cost of care affects behavior and decision-making on the part of patients and oncologists.
Asher Alban Chanan-Khan, MD, of the Mayo Clinic Cancer Center, discusses an important treatment option that significantly improved overall response rate and reduced risk of progression or death by 80% (Abstract LBA7005).
Leonard Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses how the cost of care affects behavior and decision-making on the part of patients and oncologists.
Julie Gralow, MD, of the University of Washington/Seattle Cancer Care Alliance, and Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, discuss this important SWOG trial and why oral bisphosphonates should be made available in the United States (Abstract 503).
